Skip to contentB
Biolargo, Inc.
B
BLGOBiolargo, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.37M$4.37Mderived+108.5% vs Q4 2022 Net Income-$1.02M-$1.02MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Biolargo, Inc. · CIK 880242 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$2,090,000+117.5% Operating Incomederived-$1,007,000N/M Operating Cash Flowderived-$2,000N/M Margins · derivedGross margin47.8%+2.0 pt vs Q4 2022
Operating margin-23.0%+44.5 pt vs Q4 2022
Net margin-23.3%+43.8 pt vs Q4 2022
ended Dec 31, 2023 · filed Apr 1, 2024 · 92 d after period end